Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The main output of this programme is for blood group genotyping to become embedded into routine practice. Primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.
| Supplier | Identifier | Award Value | Cross-References |
|---|---|---|---|
| NHS BLOOD AND TRANSPLANT (NHSBT) | - | £140,671 | - |